LLY logo

ELI LILLY & CO

LLYNYSE
🏆 #12 by market capEarnings Oct 29 · PreUS Equity
$1,288.78▲ $6.92 (+0.54%)
🌙 After hours$1,306.52▲ 1.38%Regular close · extended-hours price shown
🔔
Track LLY
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d▲ 1.4%
14d▲ 6.4%
30d▲ 8.7%
ytd▲ 19.9%
1y▲ 56.9%
🏦Market Cap
$1.21T
Mega Cap
📈Revenue Growth (YoY)
49.6%
High Growth
📊Gross Margin
83.4%
High
💵FCF Margin
17.0%
Healthy
⚖️P/S Ratio
15.2x
Expensive
Otter Score
80
Strong

Trading Snapshot

Day Range
$1260.34 – $1299.43
52-Week Range
$806.02 – $1,321.21
Volume (shares)
2,025,153
Avg Volume (shares)
—
Shares Outstanding
941.4M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$65.18B
Last Q Revenue
$22.97B
P/E Ratio
45.3
P/S Ratio
15.2x
EPS (TTM)
$29.80
Dividend Yield
0.48%
Dilution (1yr)
−0.6%
LLY logo

ELI LILLY & CO

LLY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$65.2B▲ +44.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.0%▲ +2.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$29.7B▲ +74.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9.0B▲ +138.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
898.0M▼ −0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$35.3B▼ −$5.0B YoY
StockOtter · stockotter.space

About ELI LILLY & CO

Pharma with leading GLP-1 franchise (Mounjaro, Zepbound).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
80/100

Analyst Ratings

ⓘ
Consensus
Buy
36 analysts
Strong Buy11
Buy20
Hold4
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Schwab Network·12h ago

Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY

Eddie Ghabour sees the Fed as the biggest risk to the current bull market. He believes the FOMC has tightened enough and believes a likely interest rate raise in December will strangle equity investors.

24/7 Wall Street·14h ago

3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast.

Investopedia·16h ago

Here's How Much Eli Lilly Stock Is Expected to Move After Earnings

Eli Lilly is set to report earnings Thursday morning, with traders expecting a move that could send the stock to a fresh high.

Benzinga·17h ago

Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings

Eli Lilly and Company (NYSE:LLY) will release its third quarter earnings report before the opening bell on Thursday, Oct. 29.

The Motley Fool·1d ago

$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today

Eli Lilly has crushed broader equities over the past five years. The company has what it takes to continue performing well over the medium term.

Reuters·1d ago

Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit

Eli Lilly said on Tuesday that Patrik Jonsson, executive vice president and president of its international business, ​will retire at the end of 2026 after a ‌36-year career at the US drugmaker.